Sydney Jennings

Results from the SPACE clinical trial showed fremanezumab reduced monthly migraine days versus placebo in children and adolescents with episodic migraine.

Your daily dose of the clinical news you may have missed.

Global trends reveal a growing burden of hypertension-related CKD despite advances in blood pressure management.

A recent study reveals declining chronic kidney disease rates in children but rising incidence among young adults, highlighting urgent public health concerns.

Your daily dose of the clinical news you may have missed.

FDA requests removal of suicidal ideation warnings from GLP-1 receptor agonist labeling after a comprehensive review found no increased risk.

Your daily dose of the clinical news you may have missed.

Weight-loss interventions significantly enhance psoriasis severity and quality of life, emphasizing their role in effective psoriasis management strategies.

Your daily dose of the clinical news you may have missed.

FDA identifies deficiencies in Anaphylm's NDA, impacting labeling discussions, while review continues for this innovative treatment for severe allergic reactions.

Your daily dose of the clinical news you may have missed.

The AHA and ACC commend the focus on fruits, vegetables, and whole grains but caution against high-fat dairy and protein emphasis.

Your daily dose of the clinical news you may have missed.

New data from the DROP-AD study suggests that dried blood spots could revolutionize screening approaches for clinical trials.

Your daily dose of the clinical news you may have missed.

COVID-19 vaccination before infection significantly reduces hospitalization, critical care admissions, and preterm birth rates in pregnant individuals, study finds.

Your daily dose of the clinical news you may have missed.

FDA prioritizes review of Tzield for young children with stage 2 type 1 diabetes, potentially delaying disease onset and improving patient outcomes.

Your daily dose of the clinical news you may have missed.

The FDA has accepted a supplemental NDA for AXS-05 for agitation associated with Alzheimer disease and granted Priority Review, with a PDUFA action date of April 30, 2026.

Stay informed with the latest critical updates, including new guidelines, vaccine insights, and groundbreaking research findings from 2025.

The FDA approved once-daily oral semaglutide 25 mg for chronic weight management and long-term weight maintenance in adults with obesity or overweight, based on data from the OASIS clinical trial program.

Abbott's Volt PFA System gains FDA approval, offering a new minimally invasive treatment for atrial fibrillation, enhancing patient care options.

Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.

Real-world patient cases illustrating how pill burden, privacy, and individual preferences influence PrEP selection and adherence.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Primary care physician Kevin Hatfield, MD, discusses how the switch can increase patient touchpoints, free cognitive burden, and strengthen long-term engagement between patients and PCPs.

Zasocitinib showed significant efficacy in treating moderate-to-severe plaque psoriasis, outperforming placebo and apremilast in pivotal phase 3 trials.

Your daily dose of the clinical news you may have missed.